Substitute for form 1449A&B/PTO				Complete if Known		
				Application Number	10/586,406	
INFO	RMATIO	N DISCLOS	SURE	Filing Date	January 19, 2005	
STATEMENT BY APPLICANT			CANT	First Named Inventor	Okabe, Ayako	
				Art Unit	1647	
(Use as many sheets as necessary)				Examiner Name	Stoica, Elly Gerald	
Sheet	1	of	1	Attorney Docket Number	082368-008400US	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US-					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	For	eign Patent D	ocument Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1	EP	1382617	A1	01-21-2004	RUAN and YE	3 17	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	2	"MedImmune discontinues rheumatoid arthritis and psoriasis trials for Vitaxin(R)." MedImmune Press Release, August 30, 2004. Retrieved from internet 05/31/07 from url: http://phx.corporate- ir.net/phoenix.zhtml?c=83037&p=irol-investornewsArticle&ID=607978&highlight=				
	3	AN, G., et al., "Expression and characterization of the ScFv fragment of antiplatelet GPIIIa monoclonal antibody SZ-21," 2002, <u>Thrombosis Research</u> , vol. 105, pp. 331-337.				
	4	HERMANN, P., et al., "The vitronectin receptor and its associated CD47 molecule mediates proinflammatory cytokine synthesis in human monocytes by interaction with soluble CD23," 1999, <u>Journal of Cell Biology</u> , vol. 144, pp. 767-775.				
	5	STORGARD, C.M., et al., "Decreased angiogenesis and arthritic disease in rabbits treated with an ανβ3 antagonist," 1999, <u>The Journal of Clinical Investigations</u> , vol. 103, pp. 47-54.				
	6	WILDER, R.L., "Integrin alpha v beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases," 2002, <u>Annals of the Rheumatic Diseases</u> , vol. 62(S2), pp. ii96-ii99.				

61179609 v1

	The second secon			
1		1]	
Examiner		Date	1	
	i			
Signature		Considered		
	<u></u>		1	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.